almonertinib + envafolimab

A combination therapy consisting of almonertinib, a third-generation EGFR tyrosine kinase inhibitor, and envafolimab, a novel PD-L1 inhibitor formulated for subcutaneous injection. This combination is being investigated primarily for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), with a particular focus on sequential therapy approaches where patients receive almonertinib followed by envafolimab upon achieving ctDNA EGFR mutation clearance and stable radiographic response. **Drug Information** Almonertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that has been approved in China for the treatment of advanced NSCLC with specific EGFR mutations. It has demonstrated good blood-brain barrier penetration, making it effective for treating central nervous system metastases[5]. Envafolimab is a novel PD-L1 inhibitor that is formulated as a subcutaneous injection. It was the first subcutaneously injectable PD-L1 inhibitor approved worldwide and the first domestic PD-L1 inhibitor approved in China in November 2021[10]. It has shown promising efficacy in treating various advanced malignant solid tumors[7]. **Clinical Development** The combination of almonertinib and envafolimab is being investigated in clinical trials, particularly for EGFR-mutant non-small cell lung cancer. One notable study (NCT05534113) is exploring a sequential therapy approach where patients first receive almonertinib treatment for 6-8 weeks, and if they achieve ctDNA EGFR mutation clearance and stable radiographic response, they then transition to envafolimab immunotherapy[1]. This sequential approach is designed to potentially overcome resistance mechanisms and improve outcomes in EGFR-mutant NSCLC patients. The study design includes monitoring ctDNA to guide treatment decisions, with patients returning to almonertinib if EGFR mutations reappear[1]. **Efficacy and Safety** While specific data on the almonertinib plus envafolimab combination is still emerging, individual components have shown promising results: - Almonertinib has demonstrated effectiveness in EGFR-mutant NSCLC, particularly in patients with brain metastases[5]. - Envafolimab has shown efficacy in various advanced solid tumors with disease control rates ranging from 36.46% to 80.77% in different clinical trials[10]. - In a retrospective study of envafolimab for advanced malignant solid tumors, the drug demonstrated safety and efficacy both as first-line therapy and in later treatment stages[7]. The combination therapy approach is part of a broader trend in oncology to combine targeted therapies (like EGFR inhibitors) with immunotherapies (like PD-L1 inhibitors) to potentially enhance anti-tumor effects and overcome resistance mechanisms. The sequential treatment strategy being investigated (almonertinib followed by envafolimab upon ctDNA clearance) represents an innovative approach to precision oncology, using biomarkers to guide treatment decisions.